Increased host responses caused by lack of IRAK-M are favorable for the clinical outcome in bacterial pneumonia [14-16], but also in tumor models [17] and bone marrow transplantation [18] which implies that inhibition of IRAK-M might have therapeutic potential. Here, IRAK3 is linked to neoplasm.